Heidelberg Pharma AG (XTER:HPHA) Effective Interest Rate on Debt % : 5.06% (As of Feb. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Heidelberg Pharma AG's annualized positive value of Interest Expense for the quarter that ended in Feb. 2025 was €0.01 Mil. Heidelberg Pharma AG's average total debt for the quarter that ended in Feb. 2025 was €0.16 Mil. Therefore, Heidelberg Pharma AG's annualized Effective Interest Rate on Debt % for the quarter that ended in Feb. 2025 was 5.06%.

Heidelberg Pharma AG Effective Interest Rate on Debt % Historical Data

The historical data trend for Heidelberg Pharma AG's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Effective Interest Rate on Debt % Chart

Heidelberg Pharma AG Annual Data

Trend

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Nov24

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

6.90

9.12

6.31

6.99

4.70

Heidelberg Pharma AG Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															13.60	86.55	4.85	2.48	5.06

Competitive Comparison of Heidelberg Pharma AG's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Heidelberg Pharma AG's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heidelberg Pharma AG's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Effective Interest Rate on Debt % falls into.

Save Embed

;

Save Embed

;

Heidelberg Pharma AG Effective Interest Rate on Debt % Calculation

Heidelberg Pharma AG's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Nov. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Nov. 2023 )	+	Total Debt (A: Nov. 2024 ))	/ count )
=	-1 * -0.141	/	( (5.831	+	0.164)	/ 2 )
=	-1 * -0.141	/	2.9975
=	4.70 %

where

	Total Debt (A: Nov. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.07	+	5.761
=	5.831

	Total Debt (A: Nov. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.049	+	0.115
=	0.164

Heidelberg Pharma AG's annualized Effective Interest Rate on Debt % for the quarter that ended in Feb. 2025 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Nov. 2024 )	+	Total Debt (Q: Feb. 2025 ))	/ count )
=	-1 * -0.008	/	( (0.164	+	0.152)	/ 2 )
=	-1 * -0.008	/	0.158
=	5.06 %

where

	Total Debt (Q: Nov. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.049	+	0.115
=	0.164

	Total Debt (Q: Feb. 2025 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.036	+	0.116
=	0.152

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Feb. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Heidelberg Pharma AG (XTER:HPHA) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Heidelberg Pharma AG Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

0QW5:UK

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Walter Miller	Board of Directors
Dr. Georg F. Baur	Supervisory Board
Prof. Dr. Andreas Pahl	Board of Directors

Heidelberg Pharma AG Headlines

No Headlines